Mersana Therapeutics, Inc. (MRSN)
Jan 6, 2026 - MRSN was delisted (reason: acquired by DAWN)
29.08
+0.04 (0.14%)
Inactive · Last trade price
on Jan 5, 2026
Mersana Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Mersana Therapeutics stock had an average target of 30.38, with a low estimate of 30 and a high estimate of 30.75.
Analyst Consensus: Buy
* Price targets were last updated on Nov 13, 2025.
Analyst Ratings
The average analyst rating for Mersana Therapeutics stock from 5 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 14, 2025 |
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $36 → $31 | Strong Buy → Hold | Downgrades | $36 → $31 | +5.74% | Nov 13, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 13, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $250 → $36 | Strong Buy | Maintains | $250 → $36 | +23.80% | Aug 14, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $125 → $30 | Strong Buy | Maintains | $125 → $30 | +3.16% | Aug 14, 2025 |
Financial Forecast
Revenue This Year
23.76M
from 40.50M
Decreased by -41.32%
Revenue Next Year
20.89M
from 23.76M
Decreased by -12.07%
EPS This Year
-8.50
from -14.12
EPS Next Year
-9.84
from -8.50
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 37.8M | 44.9M | ||||
| Avg | 23.8M | 20.9M | ||||
| Low | 14.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -6.7% | 89.1% | ||||
| Avg | -41.3% | -12.1% | ||||
| Low | -63.7% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.87 | -0.75 | |
| Avg | -8.50 | -9.84 | |
| Low | -14.90 | -16.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.